Core Insights - Beiersdorf reported a stable performance in 2025 despite economic and geopolitical uncertainties, with a focus on restoring momentum for its largest brand, NIVEA, and continuing investment in innovation and long-term growth [5][14]. Financial Performance - Beiersdorf achieved 2.4% organic sales growth for 2025, with EBIT margin increasing to 14.0%, up 10 basis points year-over-year, and earnings per share rising to EUR 4.25, a 4.9% increase compared to 2024 [14]. - The Consumer segment net sales reached EUR 8.176 billion with 2.5% organic growth, while Tesa net sales were EUR 1.676 billion, showing 1.8% organic growth [15]. Segment Performance - The Derma segment was a standout performer, with net sales reaching EUR 1.5 billion, accounting for nearly 20% of consumer net sales, and growing nearly 10% in Q4 despite tough comparisons [2][3]. - Healthcare brands Hansaplast and Elastoplast also performed strongly, achieving organic growth above 9% [7]. Market Dynamics - The global skincare market is expected to slow down significantly, with growth projected at 1.5% to 2% in 2025, particularly affecting emerging markets and Eastern Europe [4]. - NIVEA's performance in 2025 fell short of expectations due to a market slowdown, a repositioning strategy in China, and major innovations concentrated in the second half of the year [8]. Strategic Initiatives - Beiersdorf is recalibrating its NIVEA strategy to focus on strengthening categories beyond face care, maintaining global innovation platforms while allowing local flexibility, and increasing emphasis on accessible face care products [10][11]. - The company launched Epicelline into the mass market through NIVEA Cellular Epigenetic Serum, which became the strongest NIVEA face care rollout in its history [10]. Future Outlook - For 2026, Beiersdorf anticipates flat to slightly positive organic sales growth across its segments, with Q1 expected to show low single-digit negative organic growth due to softer NIVEA momentum and pressures in the luxury segment [18]. - The company plans to propose a dividend of EUR 1 per share and an additional share buyback of up to EUR 750 million over two years [17].

Palm Beach, Florida--(Newsfile Corp. - February 26, 2026) - Korean-inspired skincare brand SeoulCeuticals today published a consumer guide to PDRN (polydeoxyribonucleotide), providing safety data, effective concentration ranges, and product selection criteria as consumer search interest in the Korean bio-regenerative ingredient surged from near-zero to peak levels in under six months. The guide is available at seoulceuticals.com.OverviewConsumer interest in PDRN outpaced available education, leaving most W ...

Core Insights - Aesthetic Record has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on the integration of technology and real-world data to enhance aesthetic practices across the U.S. [1][4] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare, with over 35 years of experience and a focus on addressing various skin concerns [6]. - Aesthetic Record is the leading Electronic Medical Records (EMR) and Practice Management platform specifically designed for the medical aesthetics industry, serving thousands of practices [7][8]. Partnership Details - The partnership aims to leverage Aesthetic Record's technology to capture real-world data, enhancing the launch of Obagi's new injectable, saypha MagIQ™ [2][4]. - The ALOHA Real-World Program will provide Aesthetic Record users with hands-on experience with Obagi products, aiming to improve patient satisfaction and provider relationships [2][3]. Technology and Innovation - Obagi's saypha MagIQ™ utilizes proprietary MACRO Core Technology to create a stable hyaluronic acid matrix, designed for natural-looking results and high performance [4]. - Aesthetic Record's platform offers integrated tools for efficient charting, compliance monitoring, and performance tracking, which are essential for high-volume aesthetic practices [2][8]. Industry Impact - Initial findings from the partnership will be presented at the Aesthetic Next conference, showcasing the benefits of the new protocols and products within the Aesthetic Record ecosystem [3]. - The collaboration is positioned to advance the aesthetics industry by combining innovative injectables with streamlined technology, ultimately aiming for better patient outcomes [2].

Core Insights - DermFx has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on real-world data generation to validate the clinical safety and efficacy of Obagi's Hyaluronic Acid products in everyday practice [1][2] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [5] - DermFx is a top-ranked medical spa in Southern California, specializing in advanced aesthetic treatments and has served tens of thousands of patients over 20+ years, emphasizing exceptional patient care and personalized protocols [6][7] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8] Partnership Details - The partnership aims to provide DermFx with access to cutting-edge protocols and real-world insights, enhancing patient outcomes and allowing independent med spas to compete effectively [2][3] - The ALOHA Real-World Program will offer DermFx providers hands-on experience with Obagi saypha MagIQ™, utilizing proprietary technology for improved aesthetic results [3] Program Objectives - The ALOHA Program is designed to drive patient satisfaction and strengthen relationships between patients and DermFx providers through structured evaluations and standardized data capture [2] - Initial findings from the program will be presented at internal team meetings and regional events to highlight the benefits of the new protocols and products [2]

Core Insights - Moxie has been selected as a strategic partner for Obagi Medical's ALOHA Program due to its commitment to innovation and support for aesthetic entrepreneurs [1][3] - The partnership aims to enhance the integration of Obagi's saypha® MagIQ™ filler into aesthetic practices, leveraging Moxie's data-driven insights and operational tools [2][4] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare, with over 35 years of experience in addressing various skin concerns [5] - The company is noted for its rapid growth, being the fastest-growing professional skincare brand in the U.S. in 2024 [5] Partnership Details - The ALOHA Program will evaluate clinical performance and patient experience while providing integrated protocols to improve satisfaction and loyalty among patients [3][4] - Moxie's software and coaching will support practices of all sizes, aligning with Obagi's Aesthetics for All™ ethos [4] Product Information - Obagi's saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology for stable hyaluronic acid delivery, aiming for natural-looking results [4]

Core Insights - Obagi Medical has launched two new lip products, the Obagi Lip Therapy AHA + PHA Smoothing Micro-Peel and the Obagi Lip Therapy Soothe & Protect Lip Treatment SPF 30, as part of a targeted treatment protocol for lip care [1][2]. Product Details - The Lip Therapy protocol is designed for nightly rejuvenation and daily protection, focusing on the delicate lip area to improve texture, restore hydration, and protect against environmental stressors [2][5]. - The AHA + PHA Smoothing Micro-Peel features three resurfacing acids: Glycolic Acid, Lactic Acid, and Gluconolactone, along with Hyaluronic Acid and Argan Oil to enhance moisture retention and improve lip appearance [3][4]. - The Soothe & Protect Lip Treatment SPF 30 provides hydration and broad-spectrum sun protection, formulated with a plumping peptide complex, Calendula, Hyaluronic Acid, and Vitamin E to smooth fine lines and support the lip barrier [4]. Consumer Feedback - In consumer perception testing, a majority reported smoother, plumper, and more replenished lips immediately after application, with continued improvements in hydration and overall appearance within two weeks [5]. Company Background - Obagi Medical has over 35 years of experience in advanced skincare, initially recognized for its treatment of hyperpigmentation with the Obagi Nu-Derm® System, and is now the fastest-growing professional skincare brand in the U.S. as of 2024 [7]. Availability and Pricing - The Lip Therapy AHA + PHA Smoothing Micro-Peel is priced at $55, and the Soothe & Protect Lip Treatment SPF 30 is priced at $40, both available through professional channels and on Obagi.com starting February 3rd [6].

Core Insights - Next Health has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on personalized wellness and innovative aesthetic treatments [1] - The collaboration aims to conduct a structured assessment of Obagi's saypha MagIQ™ filler, leveraging Next Health's expertise in holistic protocols and patient-centric education [2] Company Overview - Obagi Medical is recognized for its advanced skincare solutions, with over 35 years of experience, and is the fastest-growing professional skincare brand in the U.S. as of 2024 [6][10] - Next Health, founded in 2016, specializes in health optimization and longevity, offering services like IV therapy and hormone optimization through a network of wellness centers [7] Program Details - The ALOHA Program evaluates clinical efficacy and patient experience, aiming to enhance satisfaction and loyalty through integrated Obagi protocols [3] - Standardized data will be collected across Next Health locations, with initial findings to be shared at leadership meetings and major industry conferences [3] Technology and Innovation - Obagi's saypha MagIQ™ utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed to deliver natural-looking results with high performance [4]

Core Insights - Obagi Medical has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program, highlighting a commitment to innovation and education in aesthetic medicine [1][4] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, focusing on various skin concerns including hyperpigmentation and premature aging [6] - Alpha Aesthetics Partners, founded in 2023, aims to advance the medical aesthetics industry through best-in-class support and clinical training, with a growing presence across 31 locations in 12 states [7] Program Details - The ALOHA Program will involve a structured, multi-site evaluation of Obagi's saypha MagIQ™ across Alpha's network, aiming to generate real-world evidence of the product's integration into clinical environments [2][3] - The program will collect standardized data to evaluate clinical performance and patient experience, with initial findings to be presented at the upcoming Alpha Summit [3] Product Information - Obagi's saypha MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed to deliver natural-looking results with high performance [4]

Core Insights - Obagi Medical has selected Platinum Dermatology Partners as the launch partner for its ALOHA Program, focusing on the integration of clinical evidence into everyday practice [1][2] Company Overview - Obagi Medical is recognized for its innovative physician-dispensed skincare solutions and has over 35 years of experience in the industry, particularly in treating skin concerns like hyperpigmentation and premature aging [6] - Platinum Dermatology Partners operates over 120 locations with nearly 400 providers across multiple states, emphasizing a collaborative practice model to enhance patient care [7] Program Details - The ALOHA Program aims to generate real-world data to validate the safety and efficacy of Obagi's products, specifically the saypha MagIQ injectable, through hands-on experience and structured evaluations [2][3] - Initial findings from the ALOHA Program will be presented at the annual Platinum Summit in September, showcasing the benefits of the new product within the Platinum network [4] Strategic Intent - The partnership with Platinum signifies Obagi's commitment to launching new injectables based on robust clinical evidence and integrated patient outcomes, aligning with the company's innovative approach to product development [5]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Shenzhen HBN Technology (Group) Company Limited 深圳護家科技 (集 團 )股份有限公司 (a joint stock company incorporated in the Peop ...